Tepotinib monotherapy (VISION) — MET ex14 NSCLC
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-TEPOTINIB |
|---|
| ID | REG-TEPOTINIB-NSCLC |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 SRC-VISION-PAIK-2020 |
Notes
VISION: combined cohort ORR 46% (1L 43%, pretreated 48%); mDOR 11.1 mo. Once-daily oral — convenience advantage over capmatinib BID. Edema (~70%) most common AE.
Used By
Indication
IND-NSCLC-2L-MET-EX14-TEPOTINIB- IND-NSCLC-2L-MET-EX14-TEPOTINIB